BI

Biogaia ABSTO Biogaia Stock Report

Last reporting period 30 Sep, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.704

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

BIOG B.ST Stock Analysis

BI

Attractive

Based on Eyestock quantitative analysis, BIOG B.ST`s fundamental data and valuation indicate an investment grade of Attractive at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

108/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

17.0 %

Undervalued

Market cap $B

0.704

Dividend yield

5.36 %

Shares outstanding

97.28 B

BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.

View Section: Eyestock Rating